The Epidemiology and Administration outcomes of Thrombotic Thrombocytopenic Purpura (TTP): Review article


  • Mohammed Salah Hussein Department of gastroenterology and endoscopy, Dr Samir Abbas Hospital, Jeddah, KSA- Department of internal medicine, faculty of medicine, Alazhar University hospitals, Cairo, Egypt.
  • Hussain Ali Al Baqir Resident Doctor, Al Shwaika Primary Health Care Center, Qatif, KSA.
  • Abdullah Saleh Waznah Pharmacist, King Abdulaziz Hospital, Jeddah, KSA.
  • Khalid Mater Alharbi Pharmacist, Maternity and Children Hospital, Makkah, KSA.
  • Raad Nasser Alotaibi Intern, Shaqra University, Riyadh, KSA.
  • Darraj Omar Qasem General practice – service, Gazan general hospital, KSA.
  • Saleh Saeed Alzahrani General practitioner, KSA.
  • Ali Ismail Alkudaysi Intern, King Khalid University, Abha, KSA.
  • Mushari Mana S Alqhtani General practitioner, Aseer Central Hospital, Abha, KSA.
  • Ataa Salem M Mubarak General practitioner, KSA.
  • Amal A.rahman Alwayli Arabian Gulf University.
  • Muntathir Ali Alamer Pharmacist, King Abdulaziz Hospital, Jeddah, KSA.



Thrombocytopenic Purpura (TTP), Epidemiology, Thrombocytopenia, Neurologic dysfunction


Background: Fever, thrombocytopenia, hemolysis, pentad failing kidneys, anaemia, and neurological impairment has historically been used to describe bleeding as the blood syndrome “thrombotic thrombocytopenic purpura” (TTP), a type of hemolytic anaemia caused by microangiopathy. TTP is an uncommon condition, and it is unclear exactly how often it is? According to studies, incidence per million depends on where individuals live. TTP can occur in youth with congenital forms, however it mostly strikes adults over the age of 40. The two organ systems most frequently impacted by TTP are the nerve system of the body (CNS) and kidneys. Because TTP is a serious medical condition with a 90% fatality grad if untreated, prompt diagnosis is crucial. Initial therapy is effective in around 80% of patients, and post-treatment mortality is between 10% and 15%.

Objectives: The study aimed to summarize current evidences regarding epidemiology and outcomes of Thrombotic Thrombocytopenic Purpura therapy (TTP).

Methods: For article selection, the PubMed database and EBSCO Information Services were used. All articles relevant with our topic and other articles were used in our review. Other articles that were not related to this field were excluded. The data was extracted in a specific format that was reviewed by the group members.

Conclusion: Older patients had longer Immune thrombotic thrombocytopenic purpura (iTTP) episodes and died at higher rates than younger patients. iTTP patients have a considerable increase in chance of illness and demise, while receiving TPE and immunosuppressants, which necessitate the need for more potent treatments. Moreover, they are more likely to have secondary thrombotic microangiopathies than primary microangiopathies due to several causes. Depending on the origin of thrombotic microangiopathies, there are different risks associated with dialysis, neurologic and cardiac issues, and mortality. Mortality rate are low for patients who received hospital care with low rate of complications.




How to Cite

Salah Hussein M, Ali Al Baqir H, Saleh Waznah A, Mater Alharbi K, Nasser Alotaibi R, Omar Qasem D, Saeed Alzahrani S, Ismail Alkudaysi A, Mana S Alqhtani M, Salem M Mubarak A, A.rahman Alwayli A, Ali Alamer M. The Epidemiology and Administration outcomes of Thrombotic Thrombocytopenic Purpura (TTP): Review article. SMHJ [Internet]. 2022 Nov. 24 [cited 2023 Jun. 6];2(3):124-33. Available from:



Review Article